Acumen Pharmaceuticals Inc (ABOS) Stock Price, Quote & News

Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 344 4190

Website: acumenpharm.com

Address:

1210-1220 Washington St., Suite 210, Newton, United States

Geraldgenofranco1953 Feb. 6 at 12:35 AM

$SLS $IBRX $ALT $ABOS $VSTM Count me in!

0 · Reply

jacksparo Feb. 5 at 6:06 PM

$SLS $IBRX $ALT $ABOS $VSTM Starting this coming weekend. One of my best live texting groups only for biotech to kick on This coming weekend A lot of research A lot of new 🆕 info! Great trade ideas! The first 100 members to join will get a special deal with extended membership 📈📈📈!

2 · Reply

NVDAMillionaire Feb. 4 at 8:55 AM

$ABOS Outstanding article that hits the mark on ABOS's current state. So if you want to refresh your ABOS insights or learn about ABOS from scratch, this is a must read. https://everyticker.com/quote/ABOS/analysis/acumen-pharmaceuticals-targeting-the-core-toxin-in-alzheimer-s-with-sabirnetug-nasdaq-abos

0 · Reply

jacksparo Feb. 2 at 9:39 PM

$SLS $ALT $IBRX $OCGN $ABOS Market closed . Time to review today volume and other related info 📈✅📈!

1 · Reply

Stockley_Bulbousberries Feb. 2 at 8:01 PM

$ABOS lovely

0 · Reply

h714 Feb. 2 at 7:02 PM

$ABOS have a small position

0 · Reply

Johndoe456 Jan. 30 at 8:12 PM

$ABOS

0 · Reply

B00merang Jan. 29 at 4:17 PM

$ABOS start your engines.

0 · Reply

sssssssssssssAhmed Jan. 29 at 2:26 PM

$ABOS Today will be our day

2 · Reply

StockScanners Jan. 29 at 4:33 AM

$ABOS reached 2.90

0 · Reply

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript

Sep 2, 2025, 9:28 PM EDT - 5 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 26, 2025, 4:00 PM EDT - 5 months ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2025, 2:46 PM EDT - 6 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:00 AM EDT - 6 months ago

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 4:00 PM EDT - 6 months ago

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 15, 2025, 7:00 AM EDT - 7 months ago

JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

Jul 10, 2025, 8:00 AM EDT - 7 months ago

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025

May 13, 2025, 10:11 AM EDT - 9 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:00 PM EDT - 9 months ago

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

May 6, 2025, 4:00 PM EDT - 9 months ago

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 2, 2025, 7:00 AM EDT - 11 months ago

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Mar 27, 2025, 10:05 AM EDT - 11 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 4:00 PM EDT - 11 months ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 18, 2025, 8:48 AM EDT - 11 months ago

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's

Mar 12, 2025, 8:00 AM EDT - 11 months ago

Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting

Nov 26, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 1:17 PM EST - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:05 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

LENZ

Sep 30, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Sep 25, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

Sep 3, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

Aug 13, 2024, 11:17 AM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

Jul 29, 2024, 8:38 PM EDT - 1 year ago

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease

Jul 28, 2024, 7:30 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024

May 14, 2024, 12:46 PM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

May 13, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 8, 2024, 5:47 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease

May 7, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Apr 16, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease

Mar 26, 2024, 10:45 AM EDT - 2 years ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Mar 19, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

Mar 12, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

Mar 8, 2024, 8:50 AM EST - 2 years ago

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 21, 2024, 8:00 AM EST - 2 years ago

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 1, 2024, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Jan 4, 2024, 4:15 PM EST - 2 years ago

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 4:29 PM EST - 2 years ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Nov 13, 2023, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Geraldgenofranco1953 Feb. 6 at 12:35 AM

$SLS $IBRX $ALT $ABOS $VSTM Count me in!

0 · Reply

jacksparo Feb. 5 at 6:06 PM

2 · Reply

NVDAMillionaire Feb. 4 at 8:55 AM

0 · Reply

jacksparo Feb. 2 at 9:39 PM

$SLS $ALT $IBRX $OCGN $ABOS Market closed . Time to review today volume and other related info 📈✅📈!

1 · Reply

Stockley_Bulbousberries Feb. 2 at 8:01 PM

$ABOS lovely

0 · Reply

h714 Feb. 2 at 7:02 PM

$ABOS have a small position

0 · Reply

Johndoe456 Jan. 30 at 8:12 PM

$ABOS

0 · Reply

B00merang Jan. 29 at 4:17 PM

$ABOS start your engines.

0 · Reply

sssssssssssssAhmed Jan. 29 at 2:26 PM

$ABOS Today will be our day

2 · Reply

StockScanners Jan. 29 at 4:33 AM

$ABOS reached 2.90

0 · Reply

Stock_Catcher Jan. 29 at 2:25 AM

New Video out on the Bullish Analysis on $ARBB $BNAI $BGL $ABOS $SEGG and more stocks that can Rip ! https://www.youtube.com/watch?v=nCOm_uEyME4

0 · Reply

toxicdogie Jan. 28 at 8:21 PM

$ABOS Adddd more!!! So undervalued thus bio

0 · Reply

Asher32420 Jan. 28 at 2:07 PM

$ABOS volume

0 · Reply

toxicdogie Jan. 28 at 9:58 AM

$ABOS $MRNO $AIMD $EHGO LFG!!

0 · Reply

StockScanners Jan. 28 at 5:45 AM

$ABOS keep watch if this holds above 2.70

0 · Reply

SadyK189 Jan. 28 at 4:45 AM

$ABOS Good close of daily candle. Key support at 2.1 - 2.3. Next key level to test is 3.6 - 3.85. Currently at 2.97

0 · Reply

Stock_Catcher Jan. 28 at 3:02 AM

Wealthy Wednesday Watchlist Pt. 1 $RR $WBUY $ABOS $KUST $IVF Let's Find a Big Winner Tomorrow

4 · Reply

StockJelli Jan. 28 at 3:00 AM

Ok so from our momentum screener when this was posted $RR was 18% and ended at 44%. $ABOS 16% ➡️ 30%. $HYUA ended at the same. $NET went down to 8% so it ended positive, but cooled down. Will see what tomorrow brings.

0 · Reply

Johndoe456 Jan. 28 at 1:50 AM

$ABOS

0 · Reply

TravisBking87 Jan. 28 at 12:50 AM

$ABOS Worth every penny to join your group @jacksparo!

2 · Reply

Whiskey1679 Jan. 28 at 12:19 AM

Whiskey's Penny Picks out tomorrow! I'll have 1-2 picks. See my Pinned Time Stamped Post for this mornings winner. AH Gainers: $FFIV $NXT $TXN $ABOS $MCHP

0 · Reply

StockJelli Jan. 27 at 11:27 PM

$ABOS finished 4th in our momentum scanner today! 30%❗️

0 · Reply

Market Cap	148.40M
Revenue (ttm)	0.00
Net Income (ttm)	-102.33M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.33

Volume	503,602
Avg Vol	643,626
Day's Range	N/A - N/A
Shares Out	60.57M
Stochastic %K	23%
Beta	0.24
Analysts	Strong Sell
Price Target	$7.25